Authors

Mara P. Steinkamp, Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.
Irina Lagutina, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.
Kathryn J. Brayer, Analytical and Translational Genomics Shared Resource, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.
Fred Schultz, Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Danielle Burke, Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Vernon S. Pankratz, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Sarah F. Adams, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Laurie G. Hudson, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.Department of Pharmaceutical Sciences, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Scott A. Ness, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Angela Wandinger-Ness, Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.

Document Type

Article

Publication Date

2-1-2023

Abstract

UNLABELLED: The importance of the immune microenvironment in ovarian cancer progression, metastasis, and response to therapies has become increasingly clear, especially with the new emphasis on immunotherapies. To leverage the power of patient-derived xenograft (PDX) models within a humanized immune microenvironment, three ovarian cancer PDXs were grown in humanized NBSGW (huNBSGW) mice engrafted with human CD34

SIGNIFICANCE: huPDX models are ideal preclinical models for testing novel therapies. They reflect the genetic heterogeneity of the patient population, enhance human myeloid differentiation, and recruit immune cells to the tumor microenvironment.

Share

COinS